Actualités sur la prise en charge des infections à Clostridioides difficile (notice n° 666389)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02917cam a2200373 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121194218.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Dinh, Aurélien |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Actualités sur la prise en charge des infections à Clostridioides difficile |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2023.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 56 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Clostridioides difficile infections (CDI) are a heterogeneous entity with multiple clinical presentations. The incidence of CDI has significantly increased over the last 30 years with the emergence and dissemination of hypervirulent and hyperepidemic clones which extend to the community environment. Prevention is based on reducing inappropriate antibiotic consumption, early identification of patients at risk of CDI and those who may progress to severe and/or recurrent forms. Fidaxomicin was an important therapeutic innovation and is now used as first line therapy. Oral metronidazole has no place in current therapeutic algorithms. Finally, fecal microbiota transplantation is today the treatment of choice of the 2nd recurrence. Beztoloxumab can be used in cases of ICD with a high risk of recurrence or first recurrence. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Les infections à Clostridioides difficile (ICD) sont une entité hétérogène avec de multiples présentations cliniques. L’incidence des ICD a significativement augmenté au cours des 30 dernières années avec l’émergence et la dissémination de clones hypervirulents et hyperépidémiques qui s’étendent vers le milieu communautaire. La prévention repose sur la réduction de la consommation d’antibiotique et sur l’identification précoce des patients à risque d’ICD et de ceux pouvant évoluer vers des formes sévères et/ou récidivantes.La fidaxomicine a été une importante innovation thérapeutique et est dorénavant utilisée en première ligne. Le métronidazole n’a plus sa place dans les algorithmes thérapeutiques actuels. Enfin la transplantation de microbiote fécale est aujourd’hui le traitement de choix dès la deuxième récidive. Le bezlotoxumab a une indication en cas de forme à haut risque de récidive ou de première récidive. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | colite |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | infections à |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Clostridioides difficile |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | traitement |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | infections à |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | colite |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Clostridioides difficile |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | traitement |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | infections |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | treatment |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | colitis |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Clostridioides difficile |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | treatment |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | infections |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | colitis |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Clostridioides difficile |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Fumery, Mathurin |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hépato-Gastro & Oncologie Digestive | 30 | 10 | 2023-12-05 | p. 1075-1084 | 2115-3310 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-hepato-gastro-et-oncologie-digestive-2023-10-page-1075?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-hepato-gastro-et-oncologie-digestive-2023-10-page-1075?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux